Editas Slims Down To Focus On Gene-Editing Sickle Cell Therapy Race
Needs To Catch Up With Two Rivals
Editas is seen as a slow developer in the CRISPR-based therapeutics field compared with its rivals but its new CEO has unveiled a new strategy to speed progress.
You may also be interested in...
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.